Highlights AC Immune SA

Equities

ACIU

CH0329023102

Real-time Estimate Cboe BZX Other stock markets 13:12:18 2024-05-14 EDT			5-day change	1st Jan Change
3.375 ^USD	+2.27%		+42.02%	-32.40%

05-13	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
05-13	Sector Update: Health Care	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Mixed Late Afternoon	05-13	MT
Sector Update: Health Care	05-13	MT
Top Midday Gainers	05-13	MT
AC Immune Enters Licensing Deal for Alzheimer's Disease Drug Candidate	05-13	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Ahead of Key Inflation Reports	05-13	MT
Top Premarket Gainers	05-13	MT
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate	05-13	MT
AC Immunity Shares Soar on Exclusive License Deal with Takeda	05-13	DJ
AC Immune SA Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Roche terminates licensing agreement with AC Immune	01-22	CF
AC Immune SA Announces Termination of the Research Collaboration and License Agreement with Genentech, Inc	01-22	CI
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson's Diseases	01-03	CI
AC Immune SA Announces its Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial	12-15	CI
AC Immune SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-03	CI
AC Immune SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
Companies in Alzheimer's race after US nod for Eisai/Biogen drug	23-07-07	RE
AC Immune Receives FDA Fast-Track Designation for Investigational Alzheimer's Treatment; Shares Rise Pre-Bell	23-06-27	MT
AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease	23-06-27	CI
AC Immune SA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AC Immune SA

Equities

ACIU

CH0329023102

Highlights

Filters